Other languages Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Delayed OTC Markets Other stock markets 12:46:51 2024-04-29 pm EDT			5-day change	1st Jan Change
0.92 ^USD	+14.17%		+14.64%	-23.33%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Mar. 13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	Mar. 13
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	Dec. 28
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	23-09-15
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013	23-09-07
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-08-14
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Top Premarket Gainers	23-07-12
Top Midday Gainers	23-07-11
Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients	23-06-14
Top Premarket Decliners	23-05-16
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013	23-05-02
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
Eloxx Pharmaceuticals Submits Investigational New Drug Application for Treatment of Rare Skin Disease	23-03-29
Eloxx Pharmaceuticals, Inc. Announces Submission of Investigational New Drug Application with U.S. Food and Drug Administration for ZKN-013	23-03-28
Eloxx Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed	23-02-27
Eloxx Pharmaceuticals Enrolls First Patients in Phase 2 Study of Alport Syndrome Treatment	23-01-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Other languages

Filters